ERBB2 and breast cancer: Although HR+/HER2- breast cancer is less responsive to neoadjuvant therapy than other breast cancer subtypes and PCR is difficult to obtain (9), it can still benefit from this approach, particularly in terms of improved objective tumour remission and breast conservation rates (44, 45).